mRNA |
Doxorubicin |
GDSC1000 |
pan-cancer |
AAC |
-0.071 |
0.07 |
mRNA |
Nilotinib |
CTRPv2 |
pan-cancer |
AAC |
-0.067 |
0.07 |
mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.064 |
0.07 |
mRNA |
BRD-K17060750 |
CTRPv2 |
pan-cancer |
AAC |
0.068 |
0.07 |
mRNA |
16-beta-bromoandrosterone |
CTRPv2 |
pan-cancer |
AAC |
0.068 |
0.07 |
mRNA |
PLX4720 |
CCLE |
pan-cancer |
AAC |
0.084 |
0.07 |
mRNA |
tacrolimus |
CTRPv2 |
pan-cancer |
AAC |
-0.063 |
0.07 |
mRNA |
Nilotinib |
GDSC1000 |
pan-cancer |
AAC |
-0.071 |
0.07 |
mRNA |
KU-55933 |
GDSC1000 |
pan-cancer |
AAC |
-0.069 |
0.07 |
mRNA |
Docetaxel |
CTRPv2 |
pan-cancer |
AAC |
-0.088 |
0.07 |